Home Newsfeeds UBS Upgrades iQIYI to Buy, Announces $4.8 Price Target

UBS Upgrades iQIYI to Buy, Announces $4.8 Price Target

UBS analyst Zhijing Liu upgrades iQIYI (NASDAQ:IQ) from Neutral to Buy and announces $4.8 price target.

byBenzinga Newsdesk

September 1, 2022

1 minute read

UBS analyst Zhijing Liu upgrades iQIYI (NASDAQ:IQ) from Neutral to Buy and announces $4.8 price target.

FTX, Bahamas Regulator Fight Over Control Of Bankruptcy Proceedings: WSJ

By Mehab Qureshi

November 17, 1:33 AM

Securities regulators in the Bahamas are reportedly seeking to control FTX (CRYPTO: FTT) bankruptcy proceedings, challenging the company’s Chapter 11 filing in the U.S.

$FTT

Grab Stock Is Trading Lower After Q1: Here’s The Details

By Anusuya Lahiri

May 18, 9:19 AM

Grab Holdings Limited (NASDAQ:GRAB) reported first-quarter FY23 revenue growth of 130% year-on-year (139% Y/Y on a constant currency basis)…

GRAB

McDonald’s Revenues Expected To Increase, Plus Merck And More On CNBC’s ‘Final Trades’

By Avi Kapoor

January 4, 10:11 AM

On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK)

MCD

Cytek Biosciences Expects Its FY23 Revenue To Be Near The High End Of The Co’s Most Recent Revenue Guidance Range Of $188M-1$192M

By Benzinga Newsdesk

January 8, 10:30 AM

Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023. Cytek expects its full year revenue

CTKB

UBS Upgrades iQIYI to Buy, Announces $4.8 Price Target

Related Posts

FTX, Bahamas Regulator Fight Over Control Of Bankruptcy Proceedings: WSJ

Grab Stock Is Trading Lower After Q1: Here’s The Details

McDonald’s Revenues Expected To Increase, Plus Merck And More On CNBC’s ‘Final Trades’

Cytek Biosciences Expects Its FY23 Revenue To Be Near The High End Of The Co’s Most Recent Revenue Guidance Range Of $188M-1$192M